keyword
MENU ▼
Read by QxMD icon Read
search

ER breast cancer

keyword
https://www.readbyqxmd.com/read/29678165/retrospective-analysis-of-the-impact-of-anthracycline-dose-reduction-and-chemotherapy-delays-on-the-outcomes-of-early-breast-cancer-molecular-subtypes
#1
Sigita Liutkauskiene, Saulius Grizas, Kristina Jureniene, Jorune Suipyte, Akvile Statnickaite, Elona Juozaityte
BACKGROUND: The objective of study was to determine the effect of anthracycline dose reduction and chemotherapy delays on 5-year overall survival in patients with stage I-III breast cancer, to establish the impact of molecular subtypes on the anthracycline modification effects and to analyze reasons for such chemotherapy scheme modifications. METHODS: Medical records of patients with stage I-III breast cancer were reviewed. Inclusion criteria involved stage I- III breast carcinoma; radical surgery performed and 4 courses of AC regimen (doxorubicin and cyclophosphamide), or at least 6 courses of FAC regimen (fluorouracil, doxorubicin and cyclophosphamide) completed; no neoadjuvant chemotherapy applied; no taxane group medications administered; medical records maintain comprehensive data on treatment and follow-up...
April 20, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29676234/low-dose-of-acacetin-promotes-breast-cancer-mcf-7-cells-proliferation-through-the-activation-of-erk-pi3k-akt-signaling-pathway
#2
Huanhuan Ren, Jun Ma, Lingling Si, Boxue Ren, Xiaoyu Chen, Dan Wang, Wenjin Hao, Xuexi Tang, Defang Li, Qiusheng Zheng
Background Phytoestrogens has been proposed as a replaceable medicine for climacteric hormone replacement therapy, according to EP3138562, WO/2017/019213 and US5516528. However, recent studies showed that phytoestrogens might promote the proliferation of breast cancer cells and that is associated with their estrogenic activity. Acacetin, as one phytoestrogen, has been reported to exhibit estrogenic activity. But the effects of Acacetin on breast cancer cells proliferation have not been explored Objective In this study, we evaluated the effects of acacetin on breast cancer MCF-7 cells proliferation and explored its possible mechanism...
April 20, 2018: Recent Patents on Anti-cancer Drug Discovery
https://www.readbyqxmd.com/read/29674681/publisher-correction-msk1-regulates-luminal-cell-differentiation-and-metastatic-dormancy-in-er-breast-cancer
#3
Sylwia Gawrzak, Lorenzo Rinaldi, Sara Gregorio, Enrique J Arenas, Fernando Salvador, Jelena Urosevic, Cristina Figueras-Puig, Federico Rojo, Ivan Del Barco Barrantes, Juan Miguel Cejalvo, Marta Palafox, Marc Guiu, Antonio Berenguer-Llergo, Aikaterini Symeonidi, Anna Bellmunt, Daniela Kalafatovic, Anna Arnal-Estapé, Esther Fernández, Barbara Müllauer, Rianne Groeneveld, Konstantin Slobodnyuk, Camille Stephan-Otto Attolini, Cristina Saura, Joaquín Arribas, Javier Cortes, Ana Rovira, Montse Muñoz, Ana Lluch, Violeta Serra, Joan Albanell, Aleix Prat, Angel R Nebreda, Salvador Aznar Benitah, Roger R Gomis
In the version of this Article originally published, the boxes framing the two plots in Fig. 1g were misaligned from the axes due to a technical error. This has now been corrected in all versions of the Article.
April 19, 2018: Nature Cell Biology
https://www.readbyqxmd.com/read/29673760/tumor-suppressive-functions-of-4-mu-on-breast-cancer-cells-of-different-er-status-regulation-of-hyaluronan-has2-cd44-and-specific-matrix-effectors
#4
Theodoros T Karalis, Paraskevi Heldin, Demitrios H Vynios, Thomas Neill, Simone Buraschi, Renato V Iozzo, Nikos K Karamanos, Spyros S Skandalis
The malignant phenotype of various cancers is linked to enhanced expression of hyaluronan, a pro-angiogenic glycosaminoglycan whose expression is suppressed by 4-methylumbelliferone (4-MU), a non-toxic oral agent used as a dietary supplement to improve health and combat prostate cancer. However, little is known about the effects of hyaluronan inhibition by 4-MU on breast cancer cells. In this study, we investigated the role of 4-MU in mammary carcinoma cells with distinct malignant phenotypes and estrogen receptor (ER) status, a major prognostic factor in the clinical management of breast cancers...
April 16, 2018: Matrix Biology: Journal of the International Society for Matrix Biology
https://www.readbyqxmd.com/read/29673111/comparison-of-epidemiological-features-clinicopathological-features-and-treatments-between-premenopausal-and-postmenopausal-female-breast-cancer-patients-in-western-china-a-retrospective-multicenter-study-of-15-389-female-patients
#5
REVIEW
Fan Feng, Yuxian Wei, Ke Zheng, Yujing Li, Lu Zhang, Tielin Wang, Yanli Zhang, Hongyuan Li, Guosheng Ren, Fan Li
Premenopausal and postmenopausal breast cancers are considered different types. Thus, this study aimed to explore differences in risk factors, epidemiological features, clinicopathological features, and treatment modes of premenopausal breast cancer compared to postmenopausal patients in western China. This was a hospital-based, retrospective, multicenter epidemiological study of patients with breast cancer. Using the Western China Clinical Cooperation Group database, we obtained the records of 15,389 female breast cancers between January 2010 and April 2017...
April 19, 2018: Cancer Medicine
https://www.readbyqxmd.com/read/29666928/implications-of-esr1-mutations-in-hormone-receptor-positive-breast-cancer
#6
REVIEW
Tomás Reinert, Rodrigo Gonçalves, José Bines
Endocrine treatment resistance eventually develops during adjuvant and even more often during hormonal treatment for advanced breast cancer (ABC). An ESR1 gene mutation, which encodes for the estrogen receptor (ER) protein, is one of the potential mechanisms of therapy resistance. The ESR1 mutations result in conformational changes in the ER leading to subsequent estrogen-independent transcriptional activity. These mutations are found at a lower level in early stage when compared to metastatic BC, more often through selective pressure after aromatase inhibitor (AI) treatment...
April 17, 2018: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/29665850/common-genetic-variation-and-novel-loci-associated-with-volumetric-mammographic-density
#7
Judith S Brand, Keith Humphreys, Jingmei Li, Robert Karlsson, Per Hall, Kamila Czene
BACKGROUND: Mammographic density (MD) is a strong and heritable intermediate phenotype of breast cancer, but much of its genetic variation remains unexplained. METHODS: We conducted a genetic association study of volumetric MD in a Swedish mammography screening cohort (n = 9498) to identify novel MD loci. Associations with volumetric MD phenotypes (percent dense volume, absolute dense volume, and absolute nondense volume) were estimated using linear regression adjusting for age, body mass index, menopausal status, and six principal components...
April 17, 2018: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/29665550/polyfluorinated-iodine-alkanes-regulated-distinct-breast-cancer-cell-progression-through-binding-with-estrogen-receptor-alpha-or-beta-isoforms
#8
Wenting Song, Qian S Liu, Zhendong Sun, Xiaoxi Yang, Qunfang Zhou, Guibin Jiang
Polyfluorinated iodine alkanes (PFIs) are a kind of emerging chemicals with endocrine disrupting effects. Based on the different binding preferences of PFIs to estrogen receptor alpha and beta isoforms (ERα and β), two representative PFIs, dodecafluoro-1,6-diiodohexane (PFHxDI) and tridecafluorohexyl iodide (PFHxI), were selected to evaluate their effects on the proliferation of two kinds of breast cancer cells with different ERα/β expression levels, MCF-7 and T47D. The cell viability assay showed PFHxDI could cause higher cellular toxicity than did PFHxI in both MCF-7 and T47D...
April 14, 2018: Environmental Pollution
https://www.readbyqxmd.com/read/29664714/randomized-phase-ii-trial-of-fulvestrant-plus-everolimus-or-placebo-in-postmenopausal-women-with-hormone-receptor-positive-human-epidermal-growth-factor-receptor-2-negative-metastatic-breast-cancer-resistant-to-aromatase-inhibitor-therapy-results-of-pre0102
#9
Noah Kornblum, Fengmin Zhao, Judith Manola, Paula Klein, Bhuvaneswari Ramaswamy, Adam Brufsky, Phillip J Stella, Brian Burnette, Melinda Telli, Della F Makower, Puneet Cheema, Cristina I Truica, Antonio C Wolff, Gamini S Soori, Barbara Haley, Timothy R Wassenaar, Lori J Goldstein, Kathy D Miller, Joseph A Sparano
Purpose The mammalian target of rapamycin inhibitor everolimus targets aberrant signaling through the PI3K/AKT/mammalian target of rapamycin pathway, a mechanism of resistance to anti-estrogen therapy in estrogen receptor (ER)-positive breast cancer. We hypothesized that everolimus plus the selective ER downregulator fulvestrant would be more efficacious than fulvestrant alone in ER-positive metastatic breast cancer resistant to aromatase inhibitor (AI) therapy. Patients and Methods This randomized, double-blind, placebo-controlled, phase II study included 131 postmenopausal women with ER-positive, human epidermal growth factor receptor 2-negative, AI-resistant metastatic breast cancer randomly assigned to fulvestrant (500 mg days 1 and 15 of cycle 1, then day 1 of cycles 2 and beyond) plus everolimus or placebo...
April 17, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29663173/current-status-of-neoadjuvant-endocrine-therapy-in-early-stage-breast-cancer
#10
REVIEW
Tomás Reinert, Rodrigo Gonçalves, Matthew J Ellis
Neoadjuvant endocrine therapy (NET) with Ki67-based response monitoring is a practical, cost-effective approach to the management of clinical stage II and III estrogen receptor-positive (ER+) breast cancer. In addition to marked improvements in rates of breast conservation, the identification of extreme responders on the basis of the preoperative endocrine prognostic index (PEPI) provides a rationale to avoid chemotherapy on the basis of highly favorable prognosis in some patients. Finally, samples accrued from patients treated with neoadjuvant therapy are providing valuable insights into the molecular basis for intrinsic resistance to endocrine therapy and promise a more rational basis and precise approach to the systemic treatment of ER+ breast cancer...
April 16, 2018: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/29662649/-18-fdg-pet-ct-and-molecular-markers-to-predict-response-to-neoadjuvant-chemotherapy-and-outcome-in-her2-negative-advanced-luminal-breast-cancers-patients
#11
Patricia de Cremoux, Lucie Biard, Brigitte Poirot, Philippe Bertheau, Luis Teixeira, Jacqueline Lehmann-Che, Fatiha A Bouhidel, Pascal Merlet, Marc Espié, Matthieu Resche-Rigon, Christos Sotiriou, David Groheux
Background: The efficacy of neoadjuvant chemotherapy regimens in advanced luminal breast cancer patients is difficult to predict. Intrinsic properties of breast tumors, including altered gene expression profile and dynamic evaluation of metabolic properties of tumor cells using positron emission tomography/computed tomography (PET/CT) of tumor cells, have been identified to guide patient's prognosis. The aim of this study is to determine if both analyses may improve the prediction of response to neoadjuvant chemotherapy in ER-positive / HER2-negative breast cancers (BCs) patients...
March 27, 2018: Oncotarget
https://www.readbyqxmd.com/read/29662534/obesity-and-outcome-of-post-menopausal-women-receiving-adjuvant-letrozole-for-breast-cancer
#12
Jamal Zekri, Kamel Farag, Ahmed Allithy
Introduction: Aromatase enzyme activity is predominant in adipose tissue. This has led to speculation that aromatase activity is elevated in obese women and subsequently decreased the clinical activity of adjuvant aromatase inhibitors (AIs) in women with estrogen receptor positive (ER+) breast cancer (BC). We investigated the effect of obesity on the outcome of this population. Patients and methods: Records of 320 consecutive post-menopausal (PM) women with ER+ BC starting single agent adjuvant letrozole between years 2005 and 2014 were retrospectively reviewed...
2018: Ecancermedicalscience
https://www.readbyqxmd.com/read/29662238/structural-underpinnings-of-oestrogen-receptor-mutations-in-endocrine-therapy-resistance
#13
REVIEW
John A Katzenellenbogen, Christopher G Mayne, Benita S Katzenellenbogen, Geoffrey L Greene, Sarat Chandarlapaty
Oestrogen receptor-α (ERα), a key driver of breast cancer, normally requires oestrogen for activation. Mutations that constitutively activate ERα without the need for hormone binding are frequently found in endocrine-therapy-resistant breast cancer metastases and are associated with poor patient outcomes. The location of these mutations in the ER ligand-binding domain and their impact on receptor conformation suggest that they subvert distinct mechanisms that normally maintain the low basal state of wild-type ERα in the absence of hormone...
April 16, 2018: Nature Reviews. Cancer
https://www.readbyqxmd.com/read/29662198/the-mir-106b-25-cluster-mediates-breast-tumor-initiation-through-activation-of-notch1-via-direct-repression-of-nedd4l
#14
A L Guarnieri, C G Towers, D J Drasin, M U J Oliphant, Z Andrysik, T J Hotz, R L Vartuli, E S Linklater, A Pandey, S Khanal, J M Espinosa, H L Ford
Tumor-initiating cells (TIC) represent a subset of tumor cells with increased self-renewal capability. TICs display resistance to frontline cancer treatment and retain the ability to repopulate a tumor after therapy, leading to cancer relapse. NOTCH signaling has been identified as an important driver of the TIC population, yet mechanisms governing regulation of this pathway in cancer remain to be fully elucidated. Here we identify a novel mechanism of NOTCH regulation and TIC induction in breast cancer via the miR-106b-25 miRNA cluster...
April 17, 2018: Oncogene
https://www.readbyqxmd.com/read/29661221/practice-patterns-and-outcomes-for-patients-with-node-negative-hormone-receptor-positive-breast-cancer-and-intermediate-21-gene-recurrence-scores
#15
Jonathan Chen, Xian Wu, Paul J Christos, Silvia Formenti, Himanshu Nagar
BACKGROUND: The recommendation for chemotherapy in early-stage breast cancer patients has been refined by the 21-gene Recurrence Score. However, uncertainty remains whether patients in the Intermediate Risk category benefit from chemotherapy. METHODS: We analyzed female patients from the National Cancer Database from 2006 to 2012 who had pT1c-T2N0M0 breast cancer, were ER/PR-positive and HER2-negative, received endocrine therapy, and had a 21-gene Recurrence Score from 11 to 25...
April 16, 2018: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/29658179/vav1-down-modulates-akt-in-different-breast-cancer-subtypes-a-new-promising-chance-to-improve-breast-cancer-outcome
#16
Silvia Grassilli, Federica Brugnoli, Rossano Lattanzio, Marco Marchisio, Letizia Perracchio, Mauro Piantelli, Alberto Bavelloni, Silvano Capitani, Valeria Bertagnolo
Targeting different members of the Akt pathways is a promising therapeutic chance in solid tumors including breast cancer. The variable expression levels of Akt isoforms with opposite effects on tumor growth and metastasis, however, makes it difficult to select the inhibitors to be used for specific breast tumor subtypes. By using in vitro and in vivo models, we demonstrated here that Vav1, ectopically expressed in invasive breast tumors derived cells, down-modulates Akt acting at expression and/or activation levels depending on tumor subtype...
April 15, 2018: Molecular Oncology
https://www.readbyqxmd.com/read/29651385/clinicopathological-predictors-of-long-term-benefit-in-breast-cancer-treated-with-neoadjuvant-chemotherapy
#17
Marco Galvez, Carlos A Castaneda, Joselyn Sanchez, Miluska Castillo, Lia Pamela Rebaza, Gabriela Calderon, Miguel De La Cruz, Jose Manuel Cotrina, Julio Abugattas, Jorge Dunstan, Henry Guerra, Omar Mejia, Henry L Gomez
AIM: To investigate the survival impact of clinicopathological factors, including pathological complete response (pCR) and tumor-infiltrating lymphocytes (sTIL) levels according to subtypes, in breast cancer (BC) patients who received neo-adjuvant chemotherapy (NAC). METHODS: We evaluated 435 BC patients who presented and received NAC at the Instituto Nacional de Enfermedades Neoplasicas from 2003 to 2014. sTIL was analyzed as the proportion of tumor stroma occupied by lymphocytes, and was prospectively evaluated on hematoxylin and eosin-stained sections of the preNAC core biopsy...
April 10, 2018: World Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29650929/-a-case-of-her2-positive-occult-breast-cancer-presenting-as-swollen-axillary-lymphnodes
#18
Toshiyuki Ishiba, Goshi Oda, Tsuyoshi Nakagawa, Takumi Akashi, Yamato Yamashita, Tomoki Aburatani, Taichi Ogo, Yutaka Nakashima, Hironobu Baba, Naoaki Hoshino, Yoshinobu Nishioka, Tatsuyuki Kawano
Occult breast cancer, which develops as a metastatic lesion with no primary tumor detected in the breast, is a rare breast cancer. A 68-year-old female patient particularly complained of the presence of a right axillary mass. The mass in the right axilla was palpable, but no tumor was found in both the breasts on palpation, ultrasound examination, or MRI. Partial breast resection and axillary lymph node dissection were performed following a diagnosis of invasive ductal carcinoma by core needle biopsy. There was no mammary gland tissue present around the tumor due to the pathology of the disease, and the tumor was diagnosed as occult breast cancer...
March 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29650905/-a-case-of-her2-positive-breast-cancer-with-liver-metastases-showing-three-years-of-complete-response-to-combination-therapy-with-trastuzumabplus-pertuzumab
#19
Yuri Fujimoto, Kazushige Yamaguchi, Ayako Ueno, Reo Sakurai, Yoshio Nagahisa, Shiro Imai, Kazuyuki Kawamoto
A 48-year-old woman with severe interstitial pneumonitis was diagnosed with right breast cancer(invasive ductal carcinoma, T1aN1M0, ER+, PgR-, HER2 3+)and underwent modified radical mastectomy.The patient was administered tamoxifen as adjuvant therapy.However, 1 year after the mastectomy, multiple liver metastases were found and the patient received 2 anti-HER2 agents, trastuzumab and pertuzumab.A complete response(CR)was observed with the disappearance of the liver metastases in 7 months.CR was maintained for 2 years after the initiation of treatment, and then, we started trastuzumab monotherapy, which has resulted in long-term disease control...
March 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29649162/identification-by-molecular-docking-ofhomoisoflavones-from-leopoldia-comosa-as-ligands-of-estrogen-receptors
#20
Fedora Grande, Bruno Rizzuti, Maria A Occhiuzzi, Giuseppina Ioele, Teresa Casacchia, Fabrizio Gelmini, Rita Guzzi, Antonio Garofalo, Giancarlo Statti
The physiological responses to estrogen hormones are mediated within specific tissues by at least two distinct receptors, ER and ER. Several natural and synthetic molecules show activity by interacting with these proteins. In particular, a number of vegetal compounds known as phytoestrogens shows estrogenic or anti-estrogenic activity. The majority of these compounds belongs to the isoflavones family and the most representative one, genistein, shows anti-proliferative effects on various hormone-sensitive cancer cells, including breast, ovarian and prostate cancer...
April 12, 2018: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
keyword
keyword
104906
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"